Relationship between High Sensitivity C-Reactive Protein and Total Testosterone Levels in Male Patients with Stage V Chronic Kidney Disease
DOI:
https://doi.org/10.24293/ijcpml.v28i2.1833Keywords:
Chronic kidney disease, hs-CRP, total testosterone, urea, obesity, hemodialysisAbstract
The incidence of decreased total testosterone level increases in stage V CKD patients. Decreased total testosterone levels is influenced by uremia and hemodialysis bioincompatibility through an increase in the inflammatory mediator hs-CRP. Obesity and age are risk factors of CKD incidence which can directly affect testosterone level. This study aimed to analyze the relationship between hs-CRP, serum urea, age, obesity, and hemodialysis duration with decreased total testosterone levels in stage V CKD patients. This observational study with cross-sectional approach was performed are 60 stage V CKD patients treated in Dr. Moewardi General Hospital, Surakarta on November 2020. The data were analyzed with 2x2 table test, followed by multivariate analysis using logistic regression. The examinations of total testosterone and hsRP used ECLIA and immunoturbidimetric assay, respectively. This study obtained 21 (37%) study who experienced a decreased total testosterone level (<3ng/mL). hs-CRP level [PR 3.656 (95% CI: 1.202-11,124; p=0.020)]; obesity [PR 4.156 (95% CI: 1.272-13.581; p=0.015)] and urea [PR 4.474 (95% CI: 1.273-15.728; p=0.015)] significantly associated with decreased total testosterone level of <3 ng/ml. Meanwhile age was not statistically significant (p=0.694) and hemodialysis duration obtained PR <1 and CI 95% < 1 (p=0.018). Therefore in patients with stage V, hs-CRP levels ≥ 0.65 mg/dl, serum urea ≥ 120 mg/dL, and obesity correlate with decreased total testosterone level while age is not associated with decreased total testosterone level. The hemodialysis duration is not a risk factor of decreased total testosterone.
Downloads
References
KDIGO. Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Volume 3. Issue 1. 2012. [cited at May 05, 2020]. Available at : https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf
Hill NR, Fatoba ST, Oke JL, Hirst JA, Callaghan CAO, Lasserson DS, et al. Global prevalence of chronic kiddnet disease-a systematic review and meta-analysis. Plos one. 2016; DOI:10.1371/journal.pone.0158765
IRR (Indonesian Renal Registry). 11th Report of Indonesian Renal Registry. 2018. [cited at May 07, 2020]. Available at : https://www.indonesianrenalregistry.org/data/IRR% 202018.pdf
Heidari B. C-reactive protein and other markers of inflammation in hemodialysis patients. Caspian J Intern Med. 2013; 4(1): 611-616
Imroati T.A., Thaha M., Aditiawardana, Widodo, Pranawa, Irwanadi C. Comparison of High-sensitivity C-reactive Protein Level betweem Chronic Kidney Disease Stages. Biomolecular and Health Science Journal. 2018; Vol 1 No 1. [cited at May 10, 2020]. Available at : https://e-journal.unair.ac.id/BHSJ
Ebrahimi F., Crain M.C. Metabolic syndrome and hypogonadism-two peas in a pod. Swiss Med Wkly. 2016; 146:14283
Carrero JJ., Qureshi AR., Parini P, Arver S, Lindholm, Barany P, Heimburger O, et al. Prevalence and clinical implications of testosterone deficiency in men with end stage renal disease. Nephrol Dial Transplant. 2011; 26: 184–190. doi: 10.1093/ndt/gfq397
Bargman J.M, Skorecki K. Chronic kidney disease. In : Harrison's Nephrology and Acid Base Disorders. New York : Mc Graw Hill. 2010; pp:113-115
Sherwood L. Fisiologi Manusia dari Sel ke Sistem. Edisi 2. Penerbit Buku Kedokteran EGC. Jakarta, 2002; 698-699
Dandona P., Rosenberg M.T. A practical guide to male hypogonadism in the primary care setting. Int J Clin Pract. 2010; 64(6): 682–696
Colak H., Sert I., Kurtulmus Y., Karaca Y., Karaca C., Toz H., Kursat S. The relation between serum testosterone levels and cardiovascular risk factors in patients with kidney transplantation and chronic kidney disease. Saudi J Kidney Dis Transpl; 2014; 25(5):951-959
Yuan J., Zou X.R., Han S.P., Cheng H., Wang L., Wang J.W., Zhang L.X., et al. Prevalence and risk factors for cardiovascular disease among chronic kidney disease patients : results from the Chinese cohort study of chronic kidney disease (C-STRIDE). BMC Nephrology. 2017; 18:23
Spinowitz B., Fishbane S., Update on anemia in ESRD and earlier stages of CKD : core curriculum. Am J Kidney Dis. 2018; 71(3): 423-435. doi: 10.1053/ j.ajkd.2017.09.026
Thomas L., Thomas C. 2009. Renal Failure-Measuring the Glomerular Filtration Rate. Deutsches í„rzteblatt International. 2018; 106(51–52): 849–54
Odujoko O.O., Adejumo O., Okaka E.I., Okwuonu C.G., Iyawe I. Serum C-reactive protein levels in pre-dialysis chronic kudney disease patients in southern Nigeria. 2016. [cited at November 16, 2020]. Available at : https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC4994480/pdf/ GMJ5001-0031.pdf
Mehta A., et al. Testosterone levels do not decline with age in healthy men. Open Journal of Urology. 2013; 3, 173-178, http://dx.doi.org/10.4236/oju.2013. 34032
Gungor O. Kircelli F, Carrero JJ, Asci G, Toz H, Tatar E, et al. Endogenous testosterone and mortality in male hemodialysis patients : is it the result of aging? Clin J Am Soc Nephrol. 2010; 5: 2018–2023. doi: 10.2215/CJN.03600410
Hofstra J, Loves S, Wageningen B, Koerts JR, Janssen I, Boer H. High prevalence of hypogonadotropic hypogonadism in men referred for obesity treatment. The Netherlands Journal of Medicine. 2008; 66, 3: 103-109
Bianchi V.E. The anti inflammatory effects of testosteron. J Endocr Soc. 2019; 3(1): 91–107. doi: 10.1210/js.2018-00186
Fernandez C.J., Chacko E.C., Pappachan J.M. Male obesity related secondary hypogonadism-pathophysiology, clinical implications and management. European Endocrinology. 2019; 15(2):83–90
Carrero J.J., Qureshi A.R., Parini P., Arver S., Lindholm., Barany P., Heimburger O., et al. Low serum testosterone increases mortality risk among male dialysis patients. J Am Soc Nephrol. 2009; 20: 613–620. doi: 10.1681/ASN. 2008060664
Kyriazis J., Tzanakis I, Stylianou K, Katsipi I, Moisiadis D, Papadaki A, et al. Low serum testosterone, arterial stiffness and mortality in male haemodialysis patients. Nephrol Dial Transplant. 2011; 26: 2971–2977 doi: 10.1093/ndt/gfq847
Betjes M.G. Immune cell dysfunction and inflammation in end stage renal disease. Nat. Rev. Nephrol. 2013.; doi:10.1038/nrneph.2013.44
Palmer B.F., Sexual Dysfunction in Uremia. J Am Soc Nephrol. 1999. 10: 1381–1388. [cited at November 18, 2020] Available at https://jasn.asnjournals.org/content/jnephrol/ 10/6/1381.full.pdf
Li G, Ma H, Yin Y, Wang J. CRP, IL-2 and TNF alfa level in patients with uremia receiving hemodialysis. Molecular medicine reports. 2018; DOI: 10.3892/mmr.2017.8197
Downloads
Submitted
Accepted
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
